FGF21 and metabolic dysfunction-associated steatotic liver disease: Advanced stages of NAFLD/NASH, characterized by histopathological features such as ballooning degeneration and fibrosis, may necessitate longer-term studies or alternative preclinical models (e.g., STAM mice, methionine-choline-deficient-diet-fed rodents, or humanized liver chimeric models) to fully elucidate the therapeutic potential of FGF21-164 in late-stage disease contexts.